PetLife Pharmaceuticals, Inc., a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, announced yesterday that it has retained Gregory FCA Communications, Inc., one of the nation’s largest public relations agencies, to help bring to market a breakthrough cancer treatment for pets produced from the venom of the blue scorpion.
Venom from the blue scorpion, which is native only to Haiti, Cuba, the Dominican Republic and Venezuela, has been used for more than 20 years in Cuba to treat cancer patients. Blue scorpion venom is one of the most expensive liquids in the world.
PetLife Pharmaceuticals is embarking on a series of clinical trials for its use in pets in the U.S. The announcement comes on the heels of PetLife Pharmaceuticals’ appointment of Dr. R. Geoffrey Broderick as chairman of product development. As one of the world’s most famous veterinarians, Dr. Broderick is considered the father of the natural pet food industry and who has been working for the past 50 years to reduce and prevent cancer in dogs and cats.
“Nearly 13 million pets receive a cancer diagnosis each year, and for many, it’s a death sentence,” Dr. Broderick said. “Nearly 50 percent of pets age 10 and over will die from cancer. Current treatments, including surgery and chemotherapy, are heinously expensive, barbaric and riddled with side effects. PetLife Pharmaceuticals is the first organization in the world to investigate the use of scorpion venom as a non-toxic treatment for cancer, which has the promise of saving millions of pets, while improving the quality of life for both pets and their owners.”
“PetLife Pharmaceuticals’ commitment to saving pets lives through this novel therapy is filling a desperately needed unmet medical need in veterinary care,” says Greg Matusky, president and founder of Gregory FCA. “It’s critically important that this drug becomes available to pets and their owners here in the U.S., considering the opening of relations with Cuba and recent acceptance of many medical discoveries made there.”
For instance, last fall, Roswell Park Cancer Institute in Buffalo, New York, won the right to conduct the first FDA-sanctioned study of a vaccine to treat lung cancer in humans. PetLife Pharmaceuticals sees similar parallels in its development of cancer therapies in pets.
“The advancement of this drug will serve as the culmination of more than 50 years of my work in veterinary medicine and the heartbreak I see played out over and over again with the loss of life and its devastation to families,” Dr. Broderick said. “PetLife Pharmaceuticals is working hard to produce the venom, conduct the clinical trials, and reduce the incidences of cancer in pets.”